Carlsmed’s (CARL) “Buy” Rating Reiterated at Truist Financial

Carlsmed (NASDAQ:CARL)‘s stock had its “buy” rating reissued by stock analysts at Truist Financial in a research note issued on Friday,Benzinga reports. They presently have a $20.00 target price on the stock, up from their prior target price of $18.00. Truist Financial’s price target would indicate a potential upside of 47.49% from the company’s current price.

Several other research firms have also recently weighed in on CARL. BTIG Research upped their price objective on Carlsmed from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings assumed coverage on Carlsmed in a research report on Thursday, October 16th. They set a “sell (e)” rating for the company. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $22.00.

Carlsmed Stock Up 14.0%

Shares of Carlsmed stock traded up $1.67 on Friday, hitting $13.56. The company had a trading volume of 83,234 shares, compared to its average volume of 133,518. The company has a 50-day simple moving average of $13.59. Carlsmed has a twelve month low of $11.76 and a twelve month high of $16.20.

Carlsmed (NASDAQ:CARL) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.05. Carlsmed has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. bought a new position in shares of Carlsmed during the third quarter worth approximately $37,000. Rhumbline Advisers acquired a new stake in Carlsmed during the third quarter worth about $79,000. Board of Trustees of The Leland Stanford Junior University bought a new position in Carlsmed in the third quarter valued at approximately $335,000. Kornitzer Capital Management Inc. KS acquired a new position in Carlsmed during the third quarter valued at approximately $736,000. Finally, TD Waterhouse Canada Inc. bought a new stake in Carlsmed during the third quarter worth $2,026,000.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).